Navigation Links
Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
Date:1/28/2008

Latest Version Offers Most Complete Submission Linking Capabilities

PHILADELPHIA and LONDON, Jan. 28 /PRNewswire/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced the availability of InSight Publisher(R) 3.6. The latest version of InSight Publisher adds intuitive hyperlinking and cross-reference management to its enhanced functionality set. Since its release in 2006, InSight Publisher has been enabling pharmaceutical companies to create, manage and publish regulatory submissions in both paper and electronic format using a single software application.

With the world's regulatory authorities accepting an increased number of submissions in electronic format, the need to deliver easy-to-navigate documents becomes paramount for submission success. With InSight Publisher 3.6, companies can now enable cross-referencing in all critical stages of submission development -- during authoring and submission preparation, and post publishing. By offering support at all three critical stages, InSight Publisher will help companies streamline the cross-referencing tasks and improve efficiencies during the publishing process.

Liquent expects this newest version of InSight Publisher to not only address core cross-referencing requirements, but also the new cross- referencing complexities brought on by eCTD lifecycle management such as managing cross-sequence references, stale references and more. In 2007, Liquent completed a number of worldwide implementations of InSight Publisher with its clients ahead of the project timelines and on or below budget,

"InSight Publisher continues Liquent's lea
'/>"/>

SOURCE Thomson Scientific
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Competitive Intelligence: Processes to Produce Insights that Matter
2. New insight into factors that drive muscle-building stem cells
3. Insights into cell movement likely to aid immune study, cancer research
4. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
5. New insights into deadly heart rhythm disorder
6. Neural Insights Could Bring Better Cochlear Implants
7. New technique reveals insights into lung disease
8. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
9. Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing
10. InSightec Ltd. Announces US$30 Million Investment Round
11. Cell Insights May Predict Breast Cancers Spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... about the brain affect the course of a criminal trial, ... a sentence? This was the topic of ... for Neuroscience,s "Neuroscience 2011." Titled "The Brain on Trial: Neuroscience ... neuroscience are both challenging and assisting the judicial system. To ...
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... SAN DIEGO - A new, targeted approach to treating ... Phase I/II clinical trial for patients with relapsed or ... of the American Society of Hematology. "PCI-32765, one ... cell receptor inhibitors, has shown impressive potential in this ...
... FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is easy ... your health during the flu season, but too few Americans ... off concerns about the flu, yet every year it strikes ... to the hospital and killing thousands," Dr. Thomas Slama, president ...
... Terrorist attacks with chemical weapons are a real possibility, ... access journal, Journal of Pharmacy Practice , published by ... how to treat those who have been exposed, pharmacists are ... potential chemical weapons attack. Chemical weapons act on their ...
Cached Medicine News:Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 2Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 3Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pharmacists crucial in plan for terrorist chemical weapons 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: